Evidence summary
The evidence LEDGER: stacked ruled rows, each with a persistent text state label — Established, Emerging, Not established — a fixed vocabulary. “Established practice” is state established with a display label, never a fourth enum value. The colored tick reinforces state but never carries it alone. Citations stay attached to the statement they support (ClinicalSourceList compact); the closing note is set apart by whitespace and a rule, not a tinted warning box.
Content comes from the catalog overlay's clinicalEducation.evidence; every statement must carry at least one https source (API-enforced).
import from @halwel/ui/components/product/EvidenceSummarySection
Variants
Evidence, in context
What the science says
The science is strongest for how GLP-1 medicines work. Evidence for individualized lower-dose care is developing; evidence for this exact compounded regimen is not established.
- Established
Semaglutide has dose-dependent effects
Randomized trials show that studied semaglutide doses can affect appetite, blood sugar, body weight, and adverse effects. Higher doses may produce larger average effects, but they can also increase treatment burden.
- Established practice
Dosing can be individualized
Current professional guidance supports starting low, titrating according to response and tolerability, and using less than the maximum approved dose for some patients.
- Emerging
Lower-dose treat-to-target care is being studied
A large retrospective cohort reported meaningful weight loss with individualized lower semaglutide doses plus intensive behavioral support. Because it was not randomized and had substantial attrition, it is encouraging—not conclusive.
- Not established
This exact program has not been validated in a large trial
No large randomized study has established the weight-loss, safety, cardiovascular, or longevity results of Halwel’s compounded microdose regimen. Results from FDA-approved products and studied doses should not be presented as a promise for this program.
Sources- FDA compounded semaglutide information
- Komé et al., Diabetes Care, 2025 — commentary, not trial evidence
Established mechanism. Evidence-supported personalization. Emerging lower-dose research. No claim that microdosing itself is a proven therapy.
Evidence, in context
What the science says
- Established
Semaglutide has dose-dependent effects
Randomized trials show that studied semaglutide doses can affect appetite, blood sugar, body weight, and adverse effects. Higher doses may produce larger average effects, but they can also increase treatment burden.
- Established practice
Dosing can be individualized
Current professional guidance supports starting low, titrating according to response and tolerability, and using less than the maximum approved dose for some patients.
- Emerging
Lower-dose treat-to-target care is being studied
A large retrospective cohort reported meaningful weight loss with individualized lower semaglutide doses plus intensive behavioral support. Because it was not randomized and had substantial attrition, it is encouraging—not conclusive.
- FDA compounded semaglutide information
- Komé et al., Diabetes Care, 2025 — commentary, not trial evidence